ArticleNature2023
Myelin dysfunction drives amyloid-β deposition in models of Alzheimer's disease.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 284 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
284citing papers in PubMed, 1 pooled it
47.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
284 citing papers in PubMed, 1 synthesis or guideline pooled it, 392 citations in OpenAlex.
- Advances in gait research related to Alzheimer's disease.Frontiers in neurology · 2025Pooled it
- Early axonal degeneration linked to clinical decline in Alzheimer's disease progression revealed with diffusion MRI.The Journal of clinical investigation · 2026Trial
- Accurate and well-powered case-control analysis of spatial molecular data.Nature methods · 2026Article
- Early oligodendrocyte dysfunction signature in Alzheimer's disease: Insights from DNA methylomics and transcriptomics.Molecular psychiatry · 2026Article
- Review
- Personalized single-cell transcriptomics reveals molecular diversity in Alzheimer's disease.Nature communications · 2026Article
- Beyond the Wiring: White Matter as a Dynamic Regulator of Brain Function and Disease.Neuroscience bulletin · 2026Review
- ENT1 inhibition links oligodendrocyte lipid metabolism to connectivity in tauopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Altered oligodendrocyte function promotes cognitive decline in aging.Nature medicine · 2026Article
- Oligodendrocyte-Targeted SGK1.1 Inhibition Alleviates White Matter Injury and Cognitive Impairment in Alzheimer's Disease via Modulation of HDAC2 Phosphorylation.CNS neuroscience & therapeutics · 2026Article
- Experimental induction of myelin damage in post-mortem human brain slice cultures.Acta neuropathologica communications · 2026Article
- A Novel Nogo-A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo-A/NgR/ROCK Signaling Pathway.CNS neuroscience & therapeutics · 2026Article
- Advances in Alzheimer's disease: mechanistic insights and therapeutic targets.Science China. Life sciences · 2026Review
- When myelin breaks, tau aggregates - a new perspective on Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- The Glial Autophagy-Lysosomal-Inflammation Axis in Alzheimer's Disease: a Unifying Mechanistic Framework.Molecular neurobiology · 2026Review
- Nanomedicine targeting neuroinflammatory pathways in Alzheimer's disease: a new frontier in inflammopharmacology.Inflammopharmacology · 2026Review
- Multimodal MRI combined with RNA sequencing reveals pathological signatures in the 9-month-old 3×Tg-AD mouse brain.Neural regeneration research · 2026Article
- Dissecting Alzheimer's proteomic landscape through NULISA profiling of brain cell-specific extracellular vesicles.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Altered T1w/T2w-FLAIR Ratio in White Matter Hyperintensities as an Indicator of Structural Integrity Loss: Association with Alzheimer's Disease and Vascular Dementia.medRxiv : the preprint server for health sciences · 2026Article
- Development of a Novel AAV-Mediated microRNA Gene Therapy for Spatial Suppression of BACE1 to Improve Cognitive Function in Alzheimer's Disease Model Mice.Biomolecules · 2026Article
224 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
30 authors at 7 institutions in 3 countries.
Constanze Depp *Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. depp@mpinat.mpg.de.ORCID 0000-0003-2868-6932
Ting Sun *Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0002-7104-7215
Andrew Octavian SasmitaDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Lena SpiethDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0002-0308-0144
Stefan A BerghoffDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Taisiia NazarenkoDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Katharina OverhoffDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Agnes A Steixner-KumarClinical Neuroscience, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Swati SubramanianDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Sahab ArinradClinical Neuroscience, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Torben RuhwedelDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Wiebke MöbiusDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0002-2902-7165
Sandra GöbbelsDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Gesine SaherDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0003-3507-9604
Hauke B WernerDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0002-7710-5738
Alkmini DamkouInstitute of Neuronal Cell Biology, Technical University Munich, Munich, Germany.ORCID 0000-0002-5082-0790
Silvia ZamparDepartment of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany.ORCID 0000-0003-0134-0974
Oliver WirthsDepartment of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany.ORCID 0000-0002-4115-0334
Maik ThalmannDepartment of German Philology, Georg-August University, Göttingen, Germany.ORCID 0000-0002-0610-210X
Mikael SimonsInstitute of Neuronal Cell Biology, Technical University Munich, Munich, Germany.ORCID 0000-0001-5329-192X
Takashi SaitoDepartment of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Takaomi SaidoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama, Japan.ORCID 0000-0003-1970-6903
Dilja Krueger-BurgDepartment of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany.
Riki KawaguchiProgram in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Michael WillemGerman Center for Neurodegenerative Diseases, Munich, Germany.
Christian HaassGerman Center for Neurodegenerative Diseases, Munich, Germany.ORCID 0000-0002-4869-1627
Daniel GeschwindProgram in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-2896-3450
Hannelore EhrenreichClinical Neuroscience, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0001-8371-5711
Ruth StassartDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Klaus-Armin NaveDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. nave@mpinat.mpg.de.ORCID 0000-0001-8724-9666
Max Planck Institute for Multidisciplinary SciencesGerman Center for Neurodegenerative Diseases · DEUniversity of Göttingen · DERIKEN Center for Brain Science · JPUniversity of California, Los Angeles · USMax Planck Institute for the Study of Religious and Ethnic Diversity · DEMax Planck Institute of Experimental Medicine · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of Alzheimer's disease (AD), the leading cause of dementia, increases rapidly with age, but why age constitutes the main risk factor is still poorly understood. Brain ageing affects oligodendrocytes and the structural integrity of myelin sheaths
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesMyelin SheathPlaque, AmyloidAmyloid beta-Protein PrecursorAnimalsAxonsDisease Models, AnimalDisease ProgressionMiceMicrogliaRisk FactorsSingle-Cell Gene Expression AnalysisAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.